Filing Details

Accession Number:
0001179110-13-004198
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-03-05 16:18:31
Reporting Period:
2013-02-28
Filing Date:
2013-03-05
Accepted Time:
2013-03-05 16:18:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1113481 Medicines Co MDCO Pharmaceutical Preparations (2834) 043324394
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1204787 Clive Meanwell 8 Sylvan Way
Parsippany NJ 07054
Chairman & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-02-28 474 $22.39 314,523 No 4 J Direct
Common Stock Acquisiton 2013-03-01 65,354 $0.00 379,877 No 4 A Direct
Common Stock Disposition 2013-03-01 7,500 $31.56 372,377 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 J Direct
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Options (Right to Buy) Acquisiton 2013-03-01 64,568 $31.49 64,568 $31.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
64,568 2023-03-01 No 4 A Direct
Footnotes
  1. Acquired under The Medicines Company employee stock purchase program on 2/28/2013.
  2. The common stock sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 program adopted by Dr. Meanwell on July 31, 2012.
  3. The range of prices for the transactions reported on this line is between $31.47 and $31.91 per share. The price reported above reflects the weighted average sales price. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full informaton regarding the number of shares sold at each separate price.
  4. The option vests in 48 equal monthly installments beginning on 4/1/2013.